Ocular hyperemia

Summary

Ocular hyperemia (MONDO:0001534) is a disease and 3 clinical trials. Top therapeutic interventions include naphazoline and vehicle. A subtype of conjunctival disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ocular hyperemia
Mondo ID	MONDO:0001534
DOID	DOID:1248
SNOMED CT	359610006
UMLS	C0155169
MedGen	509827
Is cancer (heuristic)	no

Also known as: hyperemia eye · hyperemia of conjunctiva

Disease family

This is a subtype of conjunctival disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › conjunctival disorder › ocular hyperemia

Related subtypes (7): conjunctival degeneration, conjunctival vascular disorder, conjunctival deposit, conjunctivochalasis, conjunctivitis, conjunctival tumor, ligneous conjunctivitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07531043	PHASE3	NOT_YET_RECRUITING	An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness
NCT07578363	PHASE3	NOT_YET_RECRUITING	An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
NCT05470868	PHASE1	COMPLETED	Safety and Tolerability of PRO-185

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NAPHAZOLINE	4	1
VEHICLE	0	2